AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27)
NCT06511895
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
57
Enrollment
INDUSTRY
Sponsor class
Conditions
Peripheral T Cell Lymphoma
Interventions
DRUG:
AZD4205
Sponsor
Dizal Pharmaceuticals